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Abstract Quercetin glucuronides are the main circulating
metabolites of quercetin in humans. We hypothesise that the
potential availability of the aglycone within tissues depends on
the substrate specificity of the deconjugating enzyme L-glucu-
ronidase towards circulating flavonoid glucuronides. Human
tissues (small intestine, liver and neutrophils) exhibited L-glucu-
ronidase against quercetin glucuronides. The various quercetin
glucuronides were deconjugated at similar rates, but liver cell-
free extracts were the most efficient and the activity was
completely inhibited by saccharo-1,4-lactone (a L-glucuronidase
inhibitor). Furthermore, pure recombinant human L-glucuroni-
dase hydrolysed various flavonoid glucuronides, with a 20-fold
variation in catalytic efficiency (kcat/Km = 1.3U103 M31 s31 for
equol-7-O-glucuronide and 26U103 M31 s31 for kaempferol-3-
O-glucuronide). Similar catalytic efficiencies were obtained for
quercetin O-glucuronides substituted at different positions. These
results show that flavonoid glucuronides can be deconjugated by
microsomal L-glucuronidase from various human cells. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The £avonoids represent the most common and widely dis-
tributed group of plant polyphenolic compounds. Quercetin, a
major £avonol, has free radical scavenging activity [1] and
many biological activities such as antioxidant, antithrombotic
and anti-carcinogenic activities [2]. Some epidemiological
studies have suggested that a high £avonol intake is associated
with a reduced incidence of cardiovascular disease [3,4].
The small intestine, as the ¢rst site of exposure to xeno-
biotics, is an important site of metabolism of £avonoids. Con-
jugation of the £avonoids in the small intestine and liver to
glucuronides, sulphates or methylated derivatives has been
shown [5^7], although the position of conjugation for many
is not known. Recently Day et al. showed that quercetin was
conjugated by uridine-diphosphate-glucuronosyltransferase
(UGT) from human liver extracts at four di¡erent hydroxyl
groups, but these conjugates had vastly di¡erent abilities to
inhibit xanthine oxidase and lipoxygenase in vitro [8].
Conjugation is a common detoxi¢cation reaction leading to
increased solubility of compounds, which is important for
excretion. Flavonoid glucuronides are likely to be excreted
in the bile due to their increased molecular weight. The £a-
vonoids can then undergo enterohepatic circulation as bacte-
rial L-glucuronidases hydrolyse the glucuronide enabling re-
absorption of the free aglycone. The liver, however, may also
play a role in the turnover of £avonoid glucuronides in vivo
due to the expression of L-glucuronidase in addition to UDP-
glucuronosyltransferase.
Human L-glucuronidase (EC 3.2.1.31) is an acid hydrolase
enzyme expressed in many tissues and body £uids [9]. There is
large interindividual variation in its activity and expression in
the liver, kidney and serum [10]. One third of the liver L-glu-
curonidase is located in the lumen of the endoplasmic retic-
ulum (ER) [11] and has been suggested to play a role in he-
patic cycling [12]. L-Glucuronidase is also found in the
lysosomal fraction of the cell [11] and has a role in hydrolysis
of steroid hormone glucuronides [13]. Thus, the activity of
L-glucuronidase may modify the net rate of glucuronide for-
mation and may in£uence the pathway of metabolism by di-
recting conjugation at speci¢c positions. The aim of this paper
was to investigate the level of L-glucuronidase activity from
various human sources towards quercetin glucuronides and
determine the a⁄nity of recombinant human L-glucuronidase
for £avonoid glucuronides conjugated at various positions.
2. Materials and methods
2.1. Materials
All material and chemical reagents were obtained from Sigma
(Poole, UK) unless otherwise stated and were analytical or HPLC
grade where applicable. Water was puri¢ed via a Millex Q plus system
(Millipore, Watford, UK). Quercetin-3-O-glucuronide was puri¢ed
from green bean tissue [14] and kaempferol-3-O-glucuronide was iso-
lated from endive [15]. Daidzein-7-O-glucuronide was chemically syn-
thesised by Needs et al. [16]. MS and NMR have previously con¢rmed
the identity of these compounds. All £avonoids were checked for
purity prior to use by HPLC and were s 98% pure. All substrates
were stored in aqueous methanol and were stable in this form at
320‡C for over 6 months. Prior to an experiment, an aliquot of the
£avonoid glucuronide stock was diluted in 20 mM sodium phosphate
bu¡er pH 7.2. The ¢nal concentration of the methanol was less than
0.3% (v/v) in the reaction mixture, which was found not to interfere
with the assay.
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2.2. Preparation of equol-7-, quercetin-4P- and
quercetin-7-O-glucuronides
General method: Solvents were dried over 3 Aî molecular sieves;
solids in vacuo over P2O5. Evaporations were performed in vacuo at
50‡C. TLC used silica 60/UV254 plates (Macherey^Nagel) eluted with
5% MeOH/CH2Cl2. Analytical HPLC, and HPLC-ESMS, using a
5 Wm Prodigy ODS3 column (250U4.4 mm) eluted at 1 ml min31
with UV detection (205, 280 nm): eluant A 80% for 5 min (isocratic);
to 10% A at 35 min (gradient). Preparative HPLC using a 5 Wm
Prodigy ODS3 column (Phenomenex Inc., 250U21.2 mm+60U21.2
mm guard) eluted at 5 ml min31. Eluant A ^ 0.1% CF3COOH
(TFA); eluant B ^ CH3CN. 80% A for 15 min (isocratic); then to
10% A at 75 min (gradient). NMR spectra were run at 27‡C on a
JEOL JNM-EX270 spectrometer using the residual solvent’s absorp-
tion for calibration. Electrospray mass spectroscopy (ESMS), and
HPLC-ESMS analyses were performed on a Micromass Quattro II
mass spectrometer (Manchester, UK).
2.3. Quercetin-7-O-glucuronide and quercetin-4P-O-glucuronide
3P,4P,4,5-Tetrabenzoylquercetin (300 mg, 420 Wmol) [17], 2,3,4,6-tet-
ra-O-acetyl-K-D-glucopyranosyl bromide (185 mg, 1.1 eq), Ag2CO3
(127 mg, 1.1 eq), 3 Aî sieves (500 mg) and dry CH2Cl2 (5 ml) were
stirred, in the dark, under Ar (5 min). Collidine (60 Wl, 1.1 eq) was
added. After 3 days, the mixture was ¢ltered (celite). The ¢ltrate and
celite rinses (5% MeOH/CH2Cl2, CH2Cl2 2U50 ml) were combined
and washed with 1 M HCl (50 ml), H2O (50 ml), 0.1 M Na2S2O3 (50
ml), H2O (50 ml), saturated NaHCO3 (50 ml), and H2O (50 ml), and
dried (MgSO4). The evaporated solid was suspended in 1 M NaOH
(20 ml), stirred under Ar (0‡, 60 min), warmed to room temperature
(rt), left for 1 h, and heated at re£ux (10 min). After cooling Dowex
50W resin (H form, 40 ml) was added, and stirred (10 min); the
mixture was ¢ltered, and ¢ltrate and resin washes (50% aq MeOH, 50
ml, MeOH 50 ml) were combined and evaporated. The resultant solid
was dissolved in 5% aq MeOH (100 ml), extracted with CH2Cl2
(3U75 ml); the aqueous phase was evaporated. The residue was dis-
solved in 50% aq MeOH (8 ml), and ¢ltered. The products were
isolated by preparative HPLC (2U4 ml injections) and were pure
by analytical HPLC. Quercetin-7-O-glucuronide. Yield 17 mg, 8%.
1H NMR (CD3OD): N 7.76 (d, 1 H, J20 ;60 2.0 Hz, H-2P), 7.66 (dd,
1 H, J60 ;50 7.6 Hz, H-6P), 6.89 (d, 1 H, H-5P), 6.74 (d, 1 H, J8;6 2.0 Hz,
H-8), 6.46 (d, 1 H, H-6), 5.14 (d, 1 H, J10 0 ;20 0 7.2 Hz, H-1Q), 4.08 (d,
1 H, J5;4 9.2 Hz, H-5Q), 3.4^3.7 (m, 3 H, H-2Q, H-3Q, H-4Q). ESMS: m/
z 479 [M+H] ; 501 [M+Na] ; 477 [M3H]3 ; 591 [M+TFA3H]3.
Quercetin-4P-glucuronide. ESMS: m/z 479 [M+H] ; 501 [M+Na] ;
477 [M3H]3 ; 591 [M+TFA3H]3.
2.4. Equol-7-O-glucuronic acid
Daidzein-7-O-glucuronic acid (20 mg, 46 Wmol) was methyl esteri-
¢ed by stirring in MeOH with Dowex 50W (H) (3 days, rt). After
¢ltration and evaporation, the residue, dissolved in EtOH (95%, 5 ml),
was added to Pd/C (10%, 50 mg). The mixture was stirred under H2
for 30 h, and ¢ltered (celite). The ¢ltrate and celite washes (MeOH, 20
ml, and 50% CH2Cl2/MeOH, 20 ml) were combined and evaporated.
After deesteri¢cation with Na2CO3 [16] the product was puri¢ed by
preparative HPLC. Yield 3 mg (15%). 1H NMR (CD3OD): N 7.10 (d,
2 H, J20 ;30 8.6 Hz, H-2P, H-6P), 6.99 (d, 1 H, J5;6 8.2 Hz, H-5), 6.76 (d,
2 H, H-3P, H-5P), 6.60 (dd, 1 H, J6;8 2.4 Hz, H-6), 6.53 (d, 1 H, H-8),
4.9 (d, 1 H, partially obscured by HOD peak, H-1Q), 4.23 (m, 1 H, H-
2a), 3.90^3.95 (m, 2 H, H-2L, H-5Q), 3.4^3.7 (m, 3 H, H-2Q, H-3Q, H-
4Q), 3.0^3.1 (m, 1 H, H-3), 2.85^2.9 (m, 2 H, 2UH-4). ESMS: m/z 417
[M-H]3.
2.5. Enzymatic synthesis of £avonoid glucuronides
Mixed quercetin glucuronides were produced enzymatically from
pig liver. Quercetin (200 WM) was incubated for 180 min at 37‡C in
HEPES bu¡er (25 mM, pH 7.2 containing 10 mM MgCl2), a post-
lysosomal fraction of pig liver, UDP-glucuronic acid (¢nal concentra-
tion, 4 mM) and UDP-glucosamine (¢nal concentration, 2 mM). The
extent of conjugation rate was greater than 95%.
2.6. Preparation of cell-free extracts
Samples of human liver were obtained from redundant tissues of
surgical specimens from patients undergoing hepatic surgery. Samples
of small intestine were purchased from Anatomic Gift Foundation
(Laurel, MD, USA). Human blood was obtained from healthy vol-
unteers. These studies were approved by the Norwich District Ethics
committee and were carried out in accordance with the Declaration of
Helsinki of the World Medical Association. All patients gave in-
formed consent to the work. A similar version of the previously pub-
lished method of Day et al. [18] to prepare cell-free extracts of human
liver and small intestine was adopted. Blood neutrophils were isolated
according to the method of Marshall et al. [19].
2.7. Assays for L-glucuronidase activity
All assays were performed at pH 7.2. p-Nitrophenol glucuronide
(p-NPGlcA, 10 mM) was incubated with cell-free extracts of human
liver, human small intestine, human faecal samples and human blood
neutrophils and sodium phosphate bu¡er (20 mM, pH 7.2) in a ¢nal
volume of 0.1 ml. All samples were incubated at 37‡C for 30 min,
during which time linear rates were obtained. Reactions were
quenched by addition of 0.9 ml 100 mM sodium borate, pH 9.3.
L-Glucuronidase activity was determined by release of p-nitrophenol
at 400 nm (E = 18 300 M31 cm31). Protein content of the human
tissues was measured using the method of Lowry et al. [20], using
bovine serum albumin as a standard. Saccharo-1,4-lactone (1 mM)
was added to some assays as indicated in the legends. A quercetin
glucuronide mixture (100 WM) was tested as a substrate under the
conditions described above. Incubations were for 180 min and were
analysed by HPLC after extraction into methanol. Human tissue sam-
ples were obtained from at least three individuals and experiments
were carried out in triplicate, with nine observations in total for
each individual. Recombinant human L-glucuronidase was prepared
as described previously by Oshima et al. [21]. To determine the Km
and Vmax, substrate was incubated with pure human recombinant
L-glucuronidase (¢nal concentration 1.1 Wg ml31) and sodium phos-
phate bu¡er in a ¢nal volume of 0.2 ml. Reactions were incubated at
37‡C for 30 min during which time the reaction rate was linear. Re-
actions were stopped by addition of 200 Wl of methanol containing
1 mM ascorbic acid, followed by centrifugation at 13 500Ug for
10 min at 4‡C. The supernatant was ¢ltered through 0.22 Wm PTFE
¢lters (Chromos Express, Maccles¢eld, UK) and analysed by HPLC.
The Km and Vmax were calculated for the various substrates using
Gra⁄t software. The data were ¢tted to Michaelis^Menten equations
and results were based on the conversion of £avonoid glucuronides to
their respective aglycones. One unit of activity is de¢ned as the
amount of enzyme releasing 1 nmol of product per min at 37‡C,
pH 7.2.
2.8. HPLC analysis
A modi¢ed version of the previously published analytical HPLC
method of Price et al. [22] was adopted. An external standard of rutin
was run approximately every six runs.
Table 1
Deconjugation of quercetin glucuronides by cell-free extracts of human small intestine, liver, neutrophils and faeces
L-Glucuronidase activity towards p-NPGlcA
(nmol mg31 protein min31)
Quercetin glucuronide deconjugation (%)
Human small intestine 3.6 þ 0.2 57 þ 14
Human liver 2.8 þ 0.3 100 þ 10
Human liver+saccharo-1,4-lactone n.d. 0 þ 2
Human neutrophils 1.5 þ 0.3 68 þ 8
Human faeces 4.0 þ 0.3 60 þ 8
Mean þ S.E.M. N = 3 independent experiments from samples from at least three individuals, with a total of nine observations. n.d., not deter-
mined.
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3. Results
Five quercetin glucuronides were produced from an incu-
bation of quercetin with a cell-free extract of pig liver (Fig. 1).
Co-elution with known quercetin glucuronide standards al-
lowed the O-conjugation position to be determined for
QG2, QG3, QG4, QG5 (3-, 7-, 4P-, 3P-), respectively. LC-
MS con¢rmed QG1 to be a quercetin di-glucuronide,
although the positions of conjugation were not further eluci-
dated.
All the human tissues investigated exhibited L-glucuroni-
dase activity towards p-NPGlcA (Table 1). Incubation of a
mixture of quercetin glucuronides with the cell-free extracts
(adjusted to have equivalent p-NPGlcA activity) demonstrated
the ability of these tissues to deconjugate quercetin glucuro-
nides (Table 1). The activity of the most active sample, liver
cell-free extract, was inhibited completely by saccharo-1,4-lac-
tone, a speci¢c L-glucuronidase inhibitor, demonstrating that
all of the activity was due to L-glucuronidase. Although the
faecal L-glucuronidase was more active than the human tis-
sues towards p-NPGlcA, quercetin glucuronides were hydro-
lysed more rapidly by human liver cell-free extracts, presum-
ably owing to the di¡erent speci¢cities of the colon micro£ora
enzymes compared to the human endogenous L-glucuroni-
dase. Fig. 2 shows the hydrolysis of the individual quercetin
glucuronides to quercetin by cell-free extracts of human blood
neutrophils. Similar pro¢les were seen for the other tissues,
illustrating that the rate of deconjugation does not appear to
be a¡ected by the position of glucuronide conjugation. The di-
glucuronide of quercetin was also hydrolysed at a similar rate
to the mono-glucuronides.
To further demonstrate that the activity in the cell-free ex-
tracts was due to L-glucuronidase, the ability of pure recombi-
nant human L-glucuronidase to hydrolyse various (iso)£avo-
noid glucuronides conjugated in various positions was
assessed. L-Glucuronidase hydrolysed both the £avonol and
iso£avone substrates, demonstrating lower Km values and
higher catalytic activity constants than that obtained for the
arti¢cial substrate, p-NPGlcA (Table 2). The Km values for all
the substrates showed a 10-fold range. However, the Km of
p-NPGlcA was much higher, indicating a much poorer appar-
ent a⁄nity. The catalytic e⁄ciency of the enzyme (kcat/Km)
showed a 20-fold di¡erence in activity. L-Glucuronidase was
active on iso£avonoid glucuronides, and the position of con-
jugation did not in£uence this activity. The catalytic activity
constants for quercetin-4P-O-glucuronide, quercetin-3-O-glu-
curonide and quercetin-7-O-glucuronide were similar, indicat-
ing that the position of conjugation does not a¡ect the activity
of L-glucuronidase.
4. Discussion
Glucuronides of £avonoids have been observed in the plas-
ma of humans and rats [5,23^25]. Conjugation with glucu-
Fig. 1. HPLC chromatogram of quercetin glucuronides. QG1 (m/z
654, m/z 303) is a di-glucuronide, QG2 (m/z 479, m/z 303) co-eluted
with quercetin-3-glucuronide, QG3 with quercetin-7-O-glucuronide,
QG4 with quercetin-4P-O-glucuronide and QG5 with quercetin-3P-O-
glucuronide standards. Similarly, Q (m/z 303) co-eluted with a quer-
cetin standard. The molar percentages of each mono-O-glucuronide
within the mixture are: 3-O-glucuronide-7-O-glucuronide, 6.5%; 4P-
O-glucuronide, 85%; 3P-O-glucuronide, 6.5%; free quercetin, 2%.
Fig. 2. Deconjugation of quercetin glucuronides by human blood
neutrophils. Total mixed quercetin glucuronides (100 WM) were in-
cubated for 180 min with cell-free extracts of human neutrophils.
(R) quercetin; (F) quercetin-4P-O-glucuronide; (8) quercetin-3/7-O-
glucuronide and (b) quercetin-3P-O-glucuronide. Errors bars repre-
sent standard error of the mean, N = 3 independent experiments
with samples obtained from at least three individuals, total of nine
observations for each individual.
Table 2
Kinetic constants for the hydrolysis of £avonol and iso£avone glucuronides by pure human recombinant L-glucuronidase
Substrate Km (WM) Vmax (U mg31 L-glucuronidase) kcat (s31) kcat/Km (M31 s31)
Kaempferol-3-O-glucuronide 25 þ 4 1179 þ 68 0.65 26.0U103
Quercetin-7-O-glucuronide 237 þ 30 2937 þ 163 1.65 6.9U103
Quercetin-3-O-glucuronide 167 þ 15 3448 þ 106 1.90 11.4U103
Quercetin-4P-O-glucuronide 48 þ 11 465 þ 45 0.26 5.4U103
Daizein-7-O-glucuronide 272 þ 30 1942 þ 82 1.07 3.9U103
Equol-7-O-glucuronide 266 þ 33 626 þ 32 0.35 1.3U103
p-NPGlcA 1400 þ 415 1221 þ 140 0.67 47
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ronic acid is mediated by UGTs, which are predominantly
located in the ER [26] and in the nuclear envelope of hepato-
cytes and cells in other organs. Microsomal L-glucuronidase is
located in the lumen of the ER where it is stabilised in a
complex with egasyn [27]. The presence of both UGT and
L-glucuronidase in close subcellular proximity within the cell
may facilitate deconjugation and therefore regulate the rate of
net glucuronidation, depending on the speci¢city of each en-
zyme. Both UGT and L-glucuronidase are active at physio-
logical pH in rat liver microsomes [28], but the optimum pH
of L-glucuronidase is between 4.5^6.0. Day et al. [8] deter-
mined the Km of UGT speci¢city towards £avonoid aglycones
in human cell-free extracts to be V5 WM. This Km is between
10^50-fold lower than the Km we obtained for L-glucuronidase
activity towards (iso)£avonoid glucuronides. In case the two
enzymes are located in the same compartment, this would
suggest that the pathway would favour the formation of glu-
curonides rather than their hydrolysis.
Although the liver is considered to be the main drug-me-
tabolising organ in the body, the intestinal mucosa often rep-
resents the ¢rst exposure site to compounds and may play a
role in ¢rst-pass metabolism of xenobiotics. Rat and human
intestinal UGT glucuronidate £avonoids (e.g. [6]). Formation
of glucuronide conjugates after passage across the small intes-
tine indicates that the form reaching and entering the hepato-
cyte is predominantly a glucuronide derivative. We have dem-
onstrated the ability of human L-glucuronidase to deconjugate
£avonoid glucuronides. However, for this process to occur,
the glucuronide must ¢rst enter the cell and then reach the
same compartment as the L-glucuronidase enzyme. This is
conceivable, since other conjugates, such as glucuronides of
bilirubin or estradiol, can be actively transported into the liver
by OATP2 [29], and paracetamol glucuronide enters cells via a
carrier mediated transporter [30].
Human eosinophils and neutrophils contain lysosomal en-
zymes that are released after cell activation. We have shown
L-glucuronidase activity in neutrophils after releasing the cell
contents and in agreement with Marshall et al. [19]. Further-
more, Shimoi et al. [31] demonstrated the release of lysosomal
L-glucuronidase from neutrophils following stimulation to in-
duce in£ammation in the cells, resulting in deconjugation of
£avone luteolin-7-O-glucuronide to luteolin. These results sug-
gest that lysosomal L-glucuronidase released from neutrophils
can deconjugate £avonoid glucuronides to the free aglycone,
when injury such as in£ammation occurs.
Mammalian microsomal and lysosomal L-glucuronidase are
derived from the same gene. They are catalytically and immu-
nologically identical but di¡er in their degree of glycosylation.
The physiological role of microsomal L-glucuronidase remains
to be elucidated. However, Whiting et al. [20] suggested a role
for microsomal L-glucuronidase in the deconjugation of bili-
rubin in rats. It has also been shown that microsomal L-glu-
curonidase activity may be stimulated and net hepatic glucu-
ronide production decreased when isolated perfused liver
receptors are activated by K-adrenergic compounds [32]. We
have shown that L-glucuronidase in human tissues could play
a role in the turnover of £avonoids, provided that the £avo-
noid conjugate reaches the same cellular compartment.
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